title: Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura.
authors.forename: Luana
authors.initials: L
authors.lastname: Benedetti
authors.forename: Diego
authors.initials: D
authors.lastname: Franciotta
authors.forename: Alessandro
authors.initials: A
authors.lastname: Beronio
authors.forename: Luigi
authors.initials: L
authors.lastname: Cadenotti
authors.forename: Marco
authors.initials: M
authors.lastname: Gobbi
authors.forename: Giovanni Luigi
authors.initials: GL
authors.lastname: Mancardi
authors.forename: Angelo
authors.initials: A
authors.lastname: Schenone
authors.forename: Antonio
authors.initials: A
authors.lastname: Tartaglione
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D004558:Electric Stimulation / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000150:complications / Q000188:drug therapy*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab